ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy of transcatheter aortic valve implantation (TAVI) compared to surgery in symptomatic women with severe aortic stenosis. It excluded patients with bicuspid aortic valve, non-calcified valve, complex coronary artery disease, or with predictors of complications for TAVI or surgery.

El estudio incluyó a 443 pacientes, aleatorizados 1:1 para recibir TAVI con dispositivos Sapien 3/3U o cirugía con cualquier válvula disponible. El punto final primario fue la incidencia de eventos adversos a un año, incluyendo mortalidad, accidente cerebrovascular (ACV) y rehospitalización.

The study enrolled 443 patients, randomized 1:1 to receive TAVI with Sapien 3/3U devices or surgery with any available valve. The primary endpoint was the incidence of adverse events at one year, including mortality, stroke, and rehospitalization.

The average age of the participants was 73 years, and they were at low risk (STS score 2.2). Between 70-75% of the women had a small aortic annulus (<430 mm²). The primary endpoint showed an event rate of 15.6% in the surgical group versus 8.9% in the TAVI group (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.34-0.88; Log-rank p=0.03). This showed both non-inferiority and superiority for TAVI in the studied events.

Breaking down the primary endpoint, the TAVI group had lower rates of mortality, stroke, and rehospitalization in particular. In terms of safety, the TAVI group had a higher incidence of vascular complications (3.3% vs. 0.5%; p=0.007) and need for pacemaker (8.8% vs. 2.9%; p=0.001), and a lower rate of atrial fibrillation (-25.5%; p<0.001).

Read also: ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation.

The authors concluded that treatment with the SAPIEN 3 or SAPIEN 3 Ultra devices showed superiority regarding the primary endpoint, with fewer rehospitalizations and less use of inpatient resources compared to surgery.

Presented by Helene Eltchaninoff at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...